ObsEva (ObsEva) Debt-to-Equity : 0.36 (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is ObsEva Debt-to-Equity?

ObsEva's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $3.03 Mil. ObsEva's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2022 was $0.00 Mil. ObsEva's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $8.48 Mil. ObsEva's debt to equity for the quarter that ended in Dec. 2022 was 0.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for ObsEva's Debt-to-Equity or its related term are showing as below:

OBSEF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

ObsEva Debt-to-Equity Historical Data

The historical data trend for ObsEva's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Debt-to-Equity Chart

ObsEva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.55

3.23

1.13

0.36

ObsEva Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Debt-to-Equity	Get a 7-Day Free Trial															1.13	1.21	-15.92	-2.94	0.36

Competitive Comparison of ObsEva's Debt-to-Equity

For the Biotechnology subindustry, ObsEva's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ObsEva's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where ObsEva's Debt-to-Equity falls into.

ObsEva Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

ObsEva's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.027	+	0)	/	8.483
	=	0.36

ObsEva's Debt to Equity Ratio for the quarter that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.027	+	0)	/	8.483
	=	0.36

ObsEva (GREY:OBSEF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

ObsEva Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of ObsEva's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

ObsEva (ObsEva) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.obseva.com

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

Executives

William Michael Brown	officer: Chief Financial Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent	director	C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan	director, officer: Chief Executive Officer	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228